PHarmaceutical tech@2x
  • News

    Most Read

    • Aruvant partners with Lonza to manufacture sickle cell disease treatment
    • Pakistan grants EUA to Sinopharm’s Covid-19 vaccine
    • Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

    Most Recent

    Drug Development

    Aruvant partners with Lonza to manufacture sickle cell disease treatment

    19 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership
    • Biden’s stimulus plan focuses on vaccine, state and local support – leading macroeconomic influencers
    • Enter Amazon Pharmacy: the beginning of a great online pharmacy fight?

    Most Recent

    Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership

    19 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
      • Respiratory

    Most Read

    • Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership
    • Aruvant partners with Lonza to manufacture sickle cell disease treatment
    • International update: Global Covid infections pass 95.6 million – WHO slams vaccine profiteers

    Most Recent

    Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership

    19 Jan 2021
  • Themes
  • Deals

    Most Read

    • Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership
    • Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m
    • NewAmsterdam Pharma raises $196m through Series A funding round

    Most Recent

    Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership

    19 Jan 2021
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • RSD
    • Kiskun Meridian
    • Baxter BioPharma Solutions

    Most Recent

    RSD

    19 Jan 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
  • Deals
  • US Election
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Powder Handling
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register

Deals this week: Cipla, Takeda Pharmaceutical, Cadila Healthcare

Indian pharmaceutical company Cipla plans to issue non-convertible debentures or bonds through a public offering...

25 May 2018

Latest News

Clinical Trials

CDSCO panel recommends approval for trial of Bharat Biotech’s nasal vaccine

20 Jan 2021
AI

Syntegra collaborates with US NIH to increase access to Covid-19 data

19 Jan 2021
Drug Development

Aruvant partners with Lonza to manufacture sickle cell disease treatment

19 Jan 2021
Regulation

Pakistan grants EUA to Sinopharm’s Covid-19 vaccine

19 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
logo-horizontal

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms & Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more